• Overview
  • Eligibility
  • More info
  • Locations
  • Results

High-Dose Chemo-Radiotherapy for Patients With Primary Refractory and Relapsed Hodgkin's Disease (NCT00003631)

National Cancer Institute (NCI)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus radiation therapy in treating patients with refractory or relapsed Hodgkin's lymphoma.
  • Biological: filgrastim
    • Drug: carboplatin
      • Drug: carmustine
        • Drug: cyclophosphamide
          • Drug: cytarabine
            • Drug: etoposide
              • Drug: ifosfamide
                • Drug: melphalan
                  • Procedure: bone marrow ablation with stem cell support
                    • Procedure: peripheral blood stem cell transplantation
                      • Radiation: radiation therapy
                        Ages eligible for Study
                        up to 120 Years
                        Genders eligible for Study
                        All
                        Accepts Healthy Volunteers
                        No
                        OBJECTIVES:

                        - Assess the efficacy of a high-dose chemoradiotherapy regimen in patients with refractory or relapsed Hodgkin's lymphoma.

                        OUTLINE: Patients are stratified into 1 of 3 treatment arms (0-1 adverse prognostic factors vs 2 adverse prognostic factors vs 3 adverse prognostic factors).

                        - Arm I (0-1 adverse prognostic factors): Patients receive ifosfamide by 24 hour infusion on day 2. Carboplatin is administered on day 2. Etoposide IV is administered once daily on days 1-3. Patients then receive filgrastim (G-CSF) subcutaneously or IV on days 5-12. Patients receive another course of ICE chemotherapy 2-3 weeks after the first course.

                        Leukapheresis is performed once WBC reaches at least 3000/mm^3 and continues until enough peripheral blood stem cells are collected.

                        Patients who have never received prior radiotherapy will receive accelerated hyperfractionated total lymphoid irradiation (TLI) twice a day for 5 days (days -10 to -6). Cyclophosphamide IV is then administered on days -5 and 4. Etoposide IV is administered by continuous infusion over 4 days (days -5 to -2).

                        Patients who have had prior radiotherapy receive high dose chemotherapy. Cyclophosphamide IV is administered on days -6 and -5. Etoposide IV is administered by continuous infusion over 4 days (days -6 to -3). Carmustine IV is administered on day -2.

                        Peripheral blood stem cells are infused 24-36 hours after high-dose chemotherapy. G-CSF is administered beginning on day 1 and continuing until blood counts recover.

                        - Arm II (2 adverse prognostic factors): Patients receive the first course of ICE as in Arm I.

                        Apheresis is performed once WBC is greater than 3000/mm^3 and continues until enough cells are collected. The second course of ICE is then administered.

                        Ifosfamide is administered by 48 hour continuous infusion on days 1-2. Carboplatin is administered on day 3. Etoposide IV is administered every 12 hours for 3 doses beginning on day 1. Patients receive G-CSF on days 5-14.

                        Patients who have never received prior radiotherapy will receive accelerated hyperfractionated TLI for 5 days (days -10 to -6). Cyclophosphamide IV is then administered every 12 hours on days -5 to -2. Etoposide IV is administered by continuous infusion over 4 days (days -5 to -2).

                        Patients who have had prior radiotherapy receive high-dose chemotherapy. Cyclophosphamide IV is administered every 12 hours on days -6 to -3. Etoposide IV is administered by continuous infusion over 4 days (days -6 to -3). Carmustine IV is administered on day -2.

                        Peripheral blood stem cells are infused 24-36 hours after high dose chemotherapy. G-CSF is administered beginning on day 1 and continuing until blood counts recover.

                        - Arm III (3 adverse prognostic factors): Patients receive cyclophosphamide IV daily for 2 days, then G-CSF beginning on day 4 until blood stem cells are collected.

                        Patients then undergo apheresis until enough cells are collected.

                        Patients receive high-dose chemotherapy. Ifosfamide IV is administered for 1 hour. Etoposide is administered by continuous infusion for 12 hours. Carboplatin IV is administered for 1 hour. Etoposide is again administered by continuous infusion for 12 hours. Treatment is repeated daily for 5 days.

                        Peripheral blood stem cells are reinfused 24-36 hours after the last dose of chemotherapy. G-CSF is administered beginning on day 1 and continuing until blood counts recover.

                        Patients who have never received prior radiation will now receive accelerated hyperfractionated TLI twice daily for 5 days. Patients receive a second course of high dose chemotherapy 45-90 days after reinfusion of cells. Etoposide IV and cytarabine IV are administered every 12 hours for 4 days (days -6 to -3). Melphalan IV is administered on day -2.

                        Patients who have received prior radiation therapy receive a second course of high-dose chemotherapy. Carmustine IV is administered on day -7. Etoposide IV and cytarabine IV are administered every 12 hours for 4 days (days -6 to -3). Melphalan IV is administered on day -2.

                        Peripheral blood stem cells are reinfused 24-48 hours after completion of second course chemotherapy. G-CSF is administered beginning on day 1 and continuing until blood counts recover.

                        Patients are followed every 3 months for the first 2 years, every 4 months during years 3-5, and every 6 months thereafter.

                        PROJECTED ACCRUAL: This study will accrue 80 patients within 4 years.

                        1 locations

                        United States (1)
                        • Memorial Sloan-Kettering Cancer Center
                          Not specified
                          New York, New York, United States, 10021
                        Participant Flow: Overall Study
                        Group A - Favorable Prognostic Group
                        Group B - Intermediate Prognostic Group
                        Group C - Unfavorable Prognostic Group
                        Serious Adverse Events
                        Group A - Favorable Prognostic Group
                        Group B - Intermediate Prognostic Group
                        Group C - Unfavorable Prognostic Group
                        Other Adverse Events
                        Group A - Favorable Prognostic Group
                        Group B - Intermediate Prognostic Group
                        Group C - Unfavorable Prognostic Group
                        Status:
                        completed
                        Type:
                        Interventional
                        Phase:
                        Start:
                        31 July, 1998
                        Updated:
                        16 December, 2015
                        Participants:
                        118
                        A girl giving information about available additional trials.

                        FindMeCure helps you find, understand and join clinical trials from all over the world.

                        There are more clinical trials for your condition!